兴齐眼药（300573）：2024年业绩高增长，期待核心产品快速放量

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 98.00 CNY per share [5][7]. Core Insights - The company achieved significant growth in 2024, with revenue reaching 1.943 billion CNY, a year-on-year increase of 32.42%, and a net profit of 348 million CNY, up 44.54% year-on-year [2][3]. - The growth is attributed to the strong sales of core products, particularly the low-concentration atropine eye drops, which were approved in March 2024 and are expected to have a large market due to the rising incidence of myopia among youth [4]. - The company has a comprehensive pipeline of ophthalmic products, covering various categories including myopia control, dry eye treatment, and anti-infection medications, which positions it well for future growth [4]. Financial Performance Summary - In 2024, the company reported revenues of 1.943 billion CNY, with the following breakdown: eye drops (1.366 billion CNY, +106.08%), gel/ointment (363 million CNY, -2.88%), medical services (133 million CNY, -62.13%), and solution (62 million CNY, +19.16%) [3]. - The projected net profits for 2025, 2026, and 2027 are estimated at 687 million CNY, 900 million CNY, and 1.137 billion CNY, representing growth rates of 103.2%, 31.0%, and 26.3% respectively [5][12]. - The expected earnings per share (EPS) for 2025 is 3.92 CNY, with a price-to-earnings (PE) ratio of 25 times [5][12].